Abstract
United States Drug Delivery Devices Investment Opportunities, Analysis and
Forecasts to 2012
Summary
This report is an essential source for in-depth information and data relating
to the USA drug delivery devices market. It also offers detailed and
comprehensive coverage of market revenue, volume, distribution and company
share information; and latest news, financial deals and pipeline products
information of each of the key sub-segments of the drug delivery devices in
USA
Scope
・ The report provides drug delivery devices information broken down into
detailed categories and segments in United States.
・ Total revenues,
products sold, end users, and average pricing.
・ Market shares of all the
key competitors.
・ Key pipeline products that are set to shape the
market, broken down by sector.
・ Information on the top medical equipment
companies in the sector in the country covering business description,
strategic analysis, and financial information.
・ Healthcare structure,
regulatory environment, approval process, pricing trends and
reimbursement.
・ Product and brand updates, strategy changes, R&D
projects, corporate expansions and contractions and regulatory changes.
・
Key mergers and acquisitions, partnerships, private equity investments and
IPOs.
・ Customer, hospitals and physicians data.
Reasons to buy
・ Gain a strong understanding of the drug delivery devices market in United
States.
・ Evaluate and compare the attractiveness of the market in the
country.
・ Identify growth segments and opportunities in each industry
sector within the country.
・ Evaluate the pipeline of key products that
will change the sector, and identify threats and opportunities before the
products are launched in the country.
・ Analyze the competitiveness of the
market in the country and identify hotspots.
・ Develop strategies based
on the latest product, brand, expansion and research and development news in
the country.
・ Do deals with an understanding of how competitors are
financed, and the mergers and partnerships that have shaped the market in the
country.
・ Identify and analyze the strengths and weaknesses of the
industry incumbents in the country.
Table of Contents
1 Table of Contents 2
1.1 List of Tables 10
1.2 List of Figures 13
2 Introduction 15
2.1 What Is This Report About? 15
2.2 Definitions
15
2.2.1 Drug delivery devices 15
2.2.1.1 Needle-free Injections
15
2.2.1.2 Inhalation Systems 15
2.2.1.3 Infusion Systems 16
3
Healthcare Sector Review 17
3.1 Healthcare Expenditure 17
3.2
Healthcare Infrastructure 22
3.2.1 Healthcare Personnel Data 24
3.2.2
Healthcare Facilities Data 27
4 Drug Delivery Devices in United States.
29
4.1 Drug Delivery Devices Overall Revenues (2000-2012) 29
4.2 Drug
Delivery Devices Overall Volume (2000-2012) 35
4.3 Drug Delivery Devices
Overall Company Shares (2005-2006) 36
5 Inhalation System in United States
37
5.1 Inhalation Systems Overall Revenues (2000-2012) 37
5.1.1
Metered Dose Inhalation Systems Overall Revenues (2000-2012) 41
5.1.2 Dry
Powder Inhalation Systems Overall Revenues (2000-2012) 43
5.2 Inhalation
Systems Overall Volume (2000-2012) 45
5.2.1 Metered Dose Inhalation
Systems Overall Volume (2000-2012) 47
5.2.2 Dry Powder Inhalation Systems
Overall Volume (2000-2012) 49
5.3 Inhalation Systems Average Price
(2000-2012) 51
5.3.1 Metered Dose Inhalation Systems Average Price
(2000-2012) 51
5.3.2 Dry Powder Inhalation Systems Average Price
(2000-2012) 53
5.4 Inhalation Systems Distribution Share (2005-2006)
55
5.5 Inhalation Systems Company Share (2005-2006) 56
6 Infusion
System in United States 57
6.1 Infusion Systems Overall Revenues
(2000-2012) 57
6.1.1 Infusion Disposable Sets Infusion System Overall
Revenues (2000-2012) 61
6.1.2 Infusion Pumps Infusion System Overall
Revenue (2000-2012) 63
6.1.3 Syringe Pumps Infusion System Overall Revenue
(2000-2012) 65
6.2 Infusion Systems Overall Volume (2000-2012) 67
6.2.1 Infusion Disposable Sets Overall Volume (2000-2012) 68
6.2.2
Infusion Pumps Overall Volume (2000-2012) 70
6.2.3 Syringe Pumps Overall
Volume (2000-2012) 72
6.3 Infusion Systems Average Price (2000-2012)
74
6.3.1 Infusion Pumps Average Price (2000-2012) 74
6.3.2 Syringe
Pumps Average Price (2000-2012) 76
6.3.3 Infusion Disposable Sets Average
Price (2000-2012) 78
6.4 Infusion Systems Distribution Share (2005-2006)
80
6.5 Infusion Systems Company Share (2005-2006) 81
7 Needle Free
Injections in United States 82
7.1 Needle Free Injections Overall Revenue
(2000-2012) 82
7.2 Needle Free Injections Category Volume (2000-2012)
84
7.3 Needle Free Injections Average Price (2000-2012) 86
7.4 Needle
Free Injections Distribution Share (2005-2006) 88
7.5 Needle Free
Injections Company Share (2005-2006) 89
8 AstraZeneca PLC Company Profile
90
8.1 Company Overview 90
8.2 Business Overview 90
8.2.1 Products
91
8.2.2 History 92
8.3 Locations And Subsidiaries 92
8.4
Financial Deals Landscape 94
8.4.1 AstraZeneca Completes $6,900 Million
Private Placement 94
8.4.2 AstraZeneca Acquires MedImmune 95
8.4.3
AstraZeneca Acquires Biologics Manufacturing Facility From DSM Biologics
97
8.4.4 AstraZeneca Acquires Arrow Therapeutics 98
8.4.5 AstraZeneca
Signs An Agreement With Palatin Technologies 100
8.4.6 AstraZeneca Signs
An Agreement With Bristol-Myers Squibb 101
8.4.7 AstraZeneca Signs An
Agreement With Cubist Pharmaceuticals 103
8.4.8 AstraZeneca Signs An
Agreement With Par Pharmaceutical 104
8.4.9 Schering Signs An Agreement
With AstraZeneca 106
8.4.10 AstraZeneca Signs An Agreement With Pozen
107
8.4.11 AstraZeneca Signs An Agreement With Abbott 109
8.4.12
AstraZeneca To Sell Its U.S Anaesthetic and Analgesic Product Portfolio To
Abraxis BioScience 110
8.4.13 AstraZeneca Acquires KuDOS Pharmaceuticals
112
8.4.14 AstraZeneca Acquires A Stake In Protherics 114
8.4.15
AstraZeneca Signs An Agreement With Targacept 115
8.4.16 AstraZeneca Signs
An Agreement With AtheroGenics 116
8.4.17 AstraZeneca UK Signs An
Agreement With Protherics 118
8.4.18 AstraZeneca Signs An Agreement With
Bayer Schering Pharma Aktiengesellschaft 120
8.4.19 AstraZeneca Signs An
Agreement With Astex Therapeutics 121
8.4.20 AstraZeneca Signs An
Agreement With Avanir Pharmaceuticals 123
8.4.21 AstraZeneca And Royal
Cosun Sells Joint Venture Advanta To Syngenta 125
8.4.22 AstraZeneca
Completes Private Placement Of $750 million 126
8.4.23 AstraZeneca Prices
EUR750 Million Private Placement 128
8.4.24 AstraZeneca Prices Sterling
Bond GBP350 Million And Euro750 Million Eurobond Private Placement 129
8.5 Recent Developments 130
8.5.1 Feb 22, 2008: AstraZeneca To Appeal
Judgment In Alabama Medical Pricing Case 130
8.5.2 Feb 18, 2008:
AstraZeneca Appoints Non-Executive Director 131
8.5.3 Dec 12, 2007:
AstraZeneca Files Patent Infringement Actions in Response to Crestor ANDAs
131
8.5.4 Sep 28, 2007: AstraZeneca Appoints New CFO 132
8.5.5 Jul 25,
2007: AstraZeneca Appoints New Board Member 132
8.5.6 Jun 06, 2007:
AstraZeneca CFO Resigns 133
8.5.7 Feb 22, 2007: AstraZeneca To Invest $120
Miilion For R&D In Macclesfield Site 133
8.5.8 Jan 30, 2007: Philips And
Leading Healthcare Companies Join For Major Research And Development 134
8.5.9 Jan 22, 2007: AstraZeneca Makes $100 Million Research Investment In
Boston 134
9 GlaxoSmithKline plc Company Profile 135
9.1 Company
Overview 135
9.2 Business Overview 135
9.2.1 Products 136
9.2.2
History 136
9.3 Locations And Subsidiaries 138
10 3M Company Profile
139
10.1 Company Overview 139
10.2 Business Overview 139
10.2.1
Consumer and Office 139
10.2.2 Display and Graphics 139
10.2.3 Electro
and Communications 140
10.2.4 Health Care 140
10.2.5 Industrial and
Transportation 141
10.2.6 Safety, Security and Protection Services 142
10.2.7 Products 142
10.3 Value Chain Analysis 144
10.3.1 Manufacturing
144
10.3.2 Product Development 145
10.3.3 Sales and Marketing 145
10.4 SWOT Analysis 146
10.4.1 3M Company Strengths 146
10.4.2 3M
Company Weaknesses 147
10.4.3 3M Company Opportunities 147
10.4.4 3M
Company Threats 148
10.5 Financial and Operational Review 149
10.6
Locations And Subsidiaries 151
11 Baxter International Company Profile
152
11.1 Company Overview 152
11.2 Business Overview 152
11.2.1
BioScience 152
11.2.2 Medication Delivery 152
11.2.3 Renal 153
11.2.4 Products 153
11.2.5 History 154
11.3 Value Chain Analysis
157
11.3.1 Manufacturing 157
11.3.2 Product Development 158
11.3.3
Sales and Marketing 158
11.4 SWOT Analysis 159
11.4.1 Baxter
International Inc. Strengths 159
11.4.2 Baxter International Inc.
Weaknesses 160
11.4.3 Baxter International Inc. Opportunities 160
11.4.4 Baxter International Inc. Threats 161
11.5 Financial and
Operational Review 162
11.6 Locations And Subsidiaries 164
11.7 Baxter
International Inc. Pipeline Products 165
11.7.1 Next-Generation Home
Hemodialysis Machine 165
11.7.1.1 Product Overview 165
11.7.1.2
Product Description 165
11.7.1.3 Product Status 166
11.7.1.4 Product
Milestone 166
12 Hospira Company Profile 167
12.1 Company Overview
167
12.2 Business Overview 167
12.2.1 Injectable Pharmaceutical Custom
Manufacturing Services Product Category 167
12.2.2 Other products,
including critical care devices Product Category 167
12.2.3 Specialty
Injectable Pharmaceuticals Product Category 167
12.2.4 Products 167
12.3 History 168
12.4 Value Chain Analysis 170
12.4.1 Manufacturing
170
12.4.2 Product Development 171
12.4.3 Sales and Marketing 172
12.5 SWOT Analysis 172
12.5.1 Hospira, Inc. Strengths 172
12.5.2
Hospira, Inc. Weaknesses 173
12.5.3 Hospira, Inc. Opportunities 173
12.5.4 Hospira, Inc. Threats 174
12.6 Financial and Operational Review
175
12.7 Locations And Subsidiaries 177
13 Regulation System 178
13.1 Medical Equipment Approval Process 178
13.1.1 Pre-market Approval
Process 179
13.1.2 Intended use and Indications for use 179
13.1.3
Predicate Device 180
13.1.4 Safe and Effective 180
13.1.5 Other
Category Devices 182
13.1.6 Post-Market Approval Process 183
13.1.7
Compliance and Enforcement 183
13.1.8 Registration Fee 184
13.1.9
Approval Time 184
14 Pricing and Reimbursement 185
14.1 Government
Policies 185
14.2 Private Insurance 186
14.3 Diagnosis Related Groups
(DRG) 187
15 Distribution Structure 188
15.1 Distribution Structure
188
16 Financial Deals Landscape 189
16.1 Private Equity 189
16.1.1 Warburg Pincus Acquires Lifecore Biomedical 189
16.2 Venture
Financing 190
16.2.1 POINT Biomedical Secures $25 Million In Venture
Financing 190
16.2.2 Medipacs Secures $1.65 Million In Financing Round
193
16.2.3 AcelRx Pharmaceuticals Secures $20.21 Million In Venture
Financing 193
16.2.4 TyRx Pharma Secures $25 Million In Venture Financing
195
16.2.5 Oriel Therapeutics Secures $23 Million In Series C Funding
196
16.3 IPO 198
16.3.1 MannKind Corporation Completes Private
Placement Of $250 Million 198
16.3.2 Delcath Systems Completes Private
Placement Of $14.2 Million 199
16.4 Debt Offerings 201
16.4.1 Bioject
Medical Completes Private Placement $1.21 Million 201
16.5 Partnership
202
16.5.1 Lupin Enters Into An Agreement With Forest Laboratories 202
16.5.2 Aethlon Medical And Delcath Systems Form Joint Venture 203
16.6
Asset Transactions 205
16.6.1 Orthofix International Sells Its Pain Care
Assets To LMA International 205
16.6.2 Boston Scientific Sells Auditory
Business And Drug Pump Development Program To Former Shareholders Of Advanced
Bionics 206
17 Recent Developments 209
17.1 Strategy And Business
Planning 209
17.1.1 Sep 02, 2008: Alpha Innotech And GE Healthcare
Announce Strategic Alliance Partnership 209
17.1.2 Aug 28, 2008: 3M
Acquires Texas Based Polyfoam 209
17.1.3 Apr 08, 2008: BD Opens New
Manufacturing Facility In Suzhou, China 210
17.2 Corporate Communications
210
17.2.1 May 29, 2008: Alexza Appoints VP, International Development
Operations 210
17.2.2 May 22, 2008: Nektar Appoints New COO 211
17.2.3
May 19, 2008: Alexza Appoints New President To Its subsidiary 211
17.2.4
May 15, 2008: Sepracor Appoints New CFO 211
17.2.5 May 15, 2008: Sepracor
CFO To Resign 212
17.2.6 May 15, 2008: Alexza Appoints New Vice President,
Quality 212
17.2.7 May 13, 2008: Vyteris Appoints President And CFO
213
17.2.8 May 13, 2008: Hospira Expands Board Of Directors 213
17.2.9
May 08, 2008: Inovio Elects New Director 214
17.2.10 May 06, 2008: Echo
Appoints Medical Advisory Board Member 214
17.2.11 Apr 02, 2008: Duska
Appoints Scientific Advisory Board Member 215
17.2.12 Mar 18, 2008: BD
Elects Vice Chairman And Board Member 215
17.3 Legal and Regulatory
216
17.3.1 Aug 19, 2008: Coughlin Stoia Files Class Action Law Suit
Against Inyx 216
17.4 Product News 216
17.4.1 Sep 09, 2008: Navilyst
Medical Introduces New EZ Huber Safety Infusion Set 216
18 Appendix
217
18.1 Methodology 217
18.2 Currency Conversion 218
18.3 Contact
Us 219
18.4 Disclaimer 219
1.1 List of Tables
Table 1: United
States Healthcare Expenditure, 2003-2010 18
Table 2: United States
Healthcare Expenditure by Age (per person), 2000-2003 19
Table 3: United
States Healthcare Expenditure by Sex (per person), 2000-2003 19
Table 4:
United States Healthcare Expenditure by Race (per person), 2000-2003 20
Table 5: United States Personal Healthcare Expenditure by Type, 2000-2004
20
Table 6: United States Personal Healthcare Expenditure by Source,
2000-2004 21
Table 7: Total Number of Doctors in the United States,
2003-2010 24
Table 8: Number of Doctors by Specialty in the United States,
2003-2010 25
Table 9: Doctors by Region (Number per 10,000 Civilian
Population), 2002-2004 26
Table 10: Doctors by Region (Number per 10,000
Civilian Population), 2002-2004 (Cont.) 27
Table 11: Total Hospitals in
the United States, 2000-2004 27
Table 12: Community Hospitals by Number of
Beds in the United States, 2000-2004 28
Table 13: Number of Hospital Beds
in the United States, 2000-2004 28
Table 14: Number of Hospital Beds by
Range in the United States, 2000-2004 28
Table 15: Drug Delivery Devices,
United States, Overall Revenues ($ mn), 2000-2012 29
Table 16: Drug
Delivery Devices, United States, Overall Revenues ($ mn), Historic, 2000-2007
30
Table 17: Drug Delivery Devices, United States, Overall Revenues ($
mn), Forecast, 2007-2012 31
Table 18: Drug Delivery Devices, United
States, Category Revenues ($ mn), 2000-2012 32
Table 19: Drug Delivery
Devices, United States, Category Revenues ($ mn), Historic, 2000-2007 33
Table 20: Drug Delivery Devices, United States, Category Revenues ($ mn),
Forecast, 2007-2012 34
Table 21: Drug Delivery Devices, United States,
Category Volume (Units), 2000-2012 35
Table 22: Drug Delivery Devices,
United States, Category Volume (Units), Historic, 2000-2007 35
Table 23:
Drug Delivery Devices, United States, Category Volume (Units), Forecast,
2007-2012 35
Table 24: Drug Delivery Devices, United States, Overall,
Company Share by Revenue ($ mn), 2005-2006 36
Table 25: Inhalation
Systems, United States, Overall Revenues ($ mn), Historic, 2000-2007 37
Table 26: Inhalation Systems, United States, Overall Revenues ($ mn),
Forecast, 2007-2012 38
Table 27: Inhalation Systems, United States,
Revenue by Segment ($ mn), Historic, 2000-2007 39
Table 28: Inhalation
Systems, United States, Revenue by Segment ($ mn), Forecast, 2007-2012 40
Table 29: Metered Dose Inhalation Systems, United States, Overall Revenues ($
mn), Historic, 2000-2007 41
Table 30: Metered Dose Inhalation Systems,
United States, Overall Revenues ($ mn), Forecast, 2007-2012 42
Table 31:
Dry Powder Inhalation Systems, United States, Overall Revenues ($ mn),
Historic, 2000-2007 43
Table 32: Dry Powder Inhalation Systems, United
States, Overall Revenues ($ mn), Forecast, 2000-2007 44
Table 33:
Inhalation Systems, United States, Overall Volume (Units), Historic, 2000-2007
45
Table 34: Inhalation Systems, United States, Overall Volume (Units),
Forecast, 2007-2012 46
Table 35: Metered Dose Inhalation Systems, United
States, Overall Volume (Units), Historic, 2000-2007 47
Table 36: Metered
Dose Inhalation Systems, United States, Overall Volume (Units), Forecast,
2007-2012 48
Table 37: Dry Powder Inhalation Systems, United States,
Overall Volume (Units), Historic, 2000-2007 49
Table 38: Dry Powder
Inhalation Systems, United States, Overall Volume (Units), Forecast, 2007-2012
50
Table 39: Metered Dose Inhalation Systems, United States, Average Price
($), Historic, 2000-2007 51
Table 40: Metered Dose Inhalation Systems,
United States, Average Price ($), Forecast, 2007-2012 52
Table 41: Dry
Powder Inhalation Systems, United States, Average Price ($), Historic,
2000-2007 53
Table 42: Dry Powder Inhalation Systems, United States,
Average Price ($), Forecast, 2007-2012 54
Table 43: Inhalation Systems,
United States, Distribution Share by Revenue ($ mn), 2005-2006 55
Table
44: Inhalation Systems, United States, Company Share by Revenue ($ mn),
2005-2006 56
Table 45: Infusion Systems, United States, Overall Revenues
($ mn), Historic, 2000-2007 57
Table 46: Infusion Systems, United States,
Overall Revenues ($ mn), Forecast, 2007-2012 58
Table 47: Infusion
Systems, United States, Revenue by Segment ($ mn), Historic, 2000-2007 59
Table 48: Infusion Systems, United States, Revenue by Segment ($ mn),
Forecast, 2007-2012 60
Table 49: Infusion Disposable Sets, United States,
Overall Revenues ($ mn), Historic, 2000-2007 61
Table 50: Infusion
Disposable Sets, United States, Overall Revenues ($ mn), Forecast, 2007-2012
62
Table 51: Infusion Pumps, United States, Overall Revenues ($ mn),
Historic, 2000-2007 63
Table 52: Infusion Pumps, United States, Overall
Revenues ($ mn), Forecast, 2007-2012 64
Table 53: Syringe Pumps, United
States, Overall Revenues ($ mn), Historic, 2000-2007 65
Table 54: Syringe
Pumps, United States, Overall Revenues ($ mn), Forecast, 2007-2012 66
Table 55: Infusion Systems, United States, Overall Volume (Units), Historic,
2000-2007 67
Table 56: Infusion Systems, United States, Overall Volume
(Units), Forecast, 2007-2012 67
Table 57: Infusion Disposable Sets, United
States, Overall Volume (Units), Historic, 2000-2007 68
Table 58: Infusion
Disposable Sets, United States, Overall Volume (Units), Forecast, 2007-2012
69
Table 59: Infusion Pumps, United States, Overall Volume (Units),
Historic, 2000-2007 70
Table 60: Infusion Pumps, United States, Overall
Volume (Units), Forecast, 2007-2012 71
Table 61: Syringe Pumps, United
States, Overall Volume (Units), Historic, 2000-2007 72
Table 62: Syringe
Pumps, United States, Overall Volume (Units), Forecast, 2007-2012 73
Table
63: Infusion Pumps, United States, Average Price ($), Historic, 2000-2007
74
Table 64: Infusion Pumps, United States, Average Price ($), Forecast,
2007-2012 75
Table 65: Syringe Pumps, United States, Average Price ($),
Historic, 2000-2007 76
Table 66: Syringe Pumps, United States, Average
Price ($), Forecast, 2007-2012 77
Table 67: Infusion Disposable Sets,
United States, Average Price ($), Historic, 2000-2007 78
Table 68:
Infusion Disposable Sets, United States, Average Price ($), Forecast,
2007-2012 79
Table 69: Infusion Systems, United States, Distribution Share
by Revenue ($ mn), 2005-2006 80
Table 70: Infusion Systems, United
States, Company Share by Revenue ($ mn), 2005-2006 81
Table 71: Needle
Free Injections, United States, Overall Revenues ($ mn), Historic, 2000-2007
82
Table 72: Needle Free Injections, United States, Overall Revenues ($
mn), Forecast, 2007-2012 83
Table 73: Needle Free Injections, United
States, Overall Volume (Units), Historic, 2000-2007 84
Table 74: Needle
Free Injections, United States, Overall Volume (Units), Forecast, 2007-2012
85
Table 75: Needle Free Injections, United States, Average Price ($),
Historic, 2000-2007 86
Table 76: Needle Free Injections, United States,
Average Price ($), Forecast, 2007-2012 87
Table 77: Needle Free
Injections, United States, Distribution Share by Revenue ($ mn), 2005-2006
88
Table 78: Needle Free Injections, United States, Company Share by
Revenue ($ mn), 2005-2006 89
Table 79: AstraZeneca PLC, Subsidiaries
93
Table 80: GlaxoSmithKline plc, Subsidiaries 138
Table 81:
3M Company, SWOT Analysis, 2006 146
Table 82: 3M Company, Financial
Statements, USD Million, 2002-2006 149
Table 83: 3M Company,
Financial Ratios, USD Million, 2002-2006 150
Table 84: 3M Company,
Subsidiaries 151
Table 85: Baxter International Inc., SWOT Analysis,
2006 159
Table 86: Baxter International Inc., Financial Statements,
USD Million, 2002-2006 162
Table 87: Baxter International Inc.,
Financial Ratios, USD Million, 2002-2006 163
Table 88: Baxter
International Inc., Other Locations 164
Table 89: Baxter
International Inc., Subsidiaries 165
Table 90: Hospira, Inc., SWOT
Analysis, 2006 172
Table 91: Hospira, Inc., Financial Statements, USD
Thousand, 2002-2006 175
Table 92: Hospira, Inc., Financial Ratios,
USD Thousand, 2002-2006 176
Table 93: Hospira, Inc., Other Locations
177
Table 94: Medical Equipment Registration Fee in United States, 2007
184
Table 95: Medical Device Approval Time in United States, 2004 184
Table 96: Currency Conversion from USD to Local Currency at 2007 Constant
Rate 218
1.2 List of Figures
Figure 1: United States, Healthcare
Expenditure by Source, 2003 18
Figure 2: United States, Healthcare
Infrastructure, Top Level View, 2007 23
Figure 3: Healthcare Expenses
Segmentation by End User, 2003 24
Figure 4: Drug Delivery Devices, United
States, Overall Revenues ($ mn), 2000-2012 29
Figure 5: Drug Delivery
Devices, United States, Overall Revenues ($ mn), Historic, 2000-2007 30
Figure 6: Drug Delivery Devices, United States, Overall Revenues ($ mn),
Forecast, 2007-2012 31
Figure 7: Drug Delivery Devices, United States,
Category Revenues ($ mn), 2000-2012 32
Figure 8: Drug Delivery Devices,
United States, Category Revenues ($ mn), Historic, 2000-2007 33
Figure 9:
Drug Delivery Devices, United States, Category Revenues ($ mn), Forecast,
2007-2012 34
Figure 10: Drug Delivery Devices, United States, Overall
Company Share (%), 2006 36
Figure 11: Inhalation Systems, United States,
Overall Revenues ($ mn), Historic, 2000-2007 37
Figure 12: Inhalation
Systems, United States, Overall Revenues ($ mn), Forecast, 2007-2012 38
Figure 13: Inhalation Systems, United States, Revenue by Segment ($ mn),
Historic, 2000-2007 39
Figure 14: Inhalation Systems, United States,
Revenue by Segment ($ mn), Forecast, 2007-2012 40
Figure 15: Metered Dose
Inhalation Systems, United States, Overall Revenues ($ mn), Historic,
2000-2007 41
Figure 16: Metered Dose Inhalation Systems, United States,
Overall Revenues ($ mn), Forecast, 2007-2012 42
Figure 17: Dry Powder
Inhalation Systems, United States, Overall Revenues ($ mn), Historic,
2000-2007 43
Figure 18: Dry Powder Inhalation Systems, United States,
Overall Revenues ($ mn), Forecast, 2007-2012 44
Figure 19: Inhalation
Systems, United States, Overall Volume (Units), Historic, 2000-2007 45
Figure 20: Inhalation Systems, United States, Overall Volume (Units),
Forecast, 2007-2012 46
Figure 21: Metered Dose Inhalation Systems, United
States, Overall Volume (Units), Historic, 2000-2007 47
Figure 22: Metered
Dose Inhalation Systems, United States, Overall Volume (Units), Forecast,
2007-2012 48
Figure 23: Dry Powder Inhalation Systems, United States,
Overall Volume (Units), Historic, 2000-2007 49
Figure 24: Dry Powder
Inhalation Systems, United States, Overall Volume (Units), Forecast, 2007-2012
50
Figure 25: Metered Dose Inhalation Systems, United States, Average
Price ($), Historic, 2000-2007 51
Figure 26: Metered Dose Inhalation
Systems, United States, Average Price ($), Forecast, 2007-2012 52
Figure
27: Dry Powder Inhalation Systems, United States, Average Price ($), Historic,
2000-2007 53
Figure 28: Dry Powder Inhalation Systems, United States,
Average Price ($), Forecast, 2007-2012 54
Figure 29: Inhalation Systems,
United States, Distribution Share (%), 2005-2006 55
Figure 30: Inhalation
Systems, United States, Company Share (%), 2006 56
Figure 31: Infusion
Systems, United States, Overall Revenues ($ mn), Historic, 2000-2007 57
Figure 32: Infusion Systems, United States, Overall Revenues ($ mn), Forecast,
2007-2012 58
Figure 33: Infusion Systems, United States, Revenue by
Segment ($ mn), Historic, 2000-2007 59
Figure 34: Infusion Systems, United
States, Revenue by Segment ($ mn), Forecast, 2007-2012 60
Figure 35:
Infusion Disposable Sets, United States, Overall Revenues ($ mn), Historic,
2000-2007 61
Figure 36: Infusion Disposable Sets, United States, Overall
Revenues ($ mn), Forecast, 2007-2012 62
Figure 37: Infusion Pumps, United
States, Overall Revenues ($ mn), Historic, 2000-2007 63
Figure 38:
Infusion Pumps, United States, Overall Revenues ($ mn), Forecast, 2007-2012
64
Figure 39: Syringe Pumps, United States, Overall Revenues ($ mn),
Historic, 2000-2007 65
Figure 40: Syringe Pumps, United States, Overall
Revenues ($ mn), Forecast, 2007-2012 66
Figure 41: Infusion Disposable
Sets, United States, Overall Volume (Units), Historic, 2000-2007 68
Figure
42: Infusion Disposable Sets, United States, Overall Volume (Units), Forecast,
2007-2012 69
Figure 43: Infusion Pumps, United States, Overall Volume
(Units), Historic, 2000-2007 70
Figure 44: Infusion Pumps, United States,
Overall Volume (Units), Forecast, 2007-2012 71
Figure 45: Syringe Pumps,
United States, Overall Volume (Units), Historic, 2000-2007 72
Figure 46:
Syringe Pumps, United States, Overall Volume (Units), Forecast, 2007-2012
73
Figure 47: Infusion Pumps, United States, Average Price ($), Historic,
2000-2007 74
Figure 48: Infusion Pumps, United States, Average Price ($),
Forecast, 2007-2012 75
Figure 49: Syringe Pumps, United States, Average
Price ($), Historic, 2000-2007 76
Figure 50: Syringe Pumps, United States,
Average Price ($), Forecast, 2007-2012 77
Figure 51: Infusion Disposable
Sets, United States, Average Price ($), Historic, 2000-2007 78
Figure 52:
Infusion Disposable Sets, United States, Average Price ($), Forecast,
2007-2012 79
Figure 53: Infusion Systems, United States, Distribution
Share (%), 2006 80
Figure 54: Infusion Systems, United States, Company
Share (%), 2006 81
Figure 55: Needle Free Injections, United States,
Overall Revenues ($ mn), Historic, 2000-2007 82
Figure 56: Needle Free
Injections, United States, Overall Revenues ($ mn), Forecast, 2007-2012 83
Figure 57: Needle Free Injections, United States, Overall Volume (Units),
Historic, 2000-2007 84
Figure 58: Needle Free Injections, United States,
Overall Volume (Units), Forecast, 2007-2012 85
Figure 59: Needle Free
Injections, United States, Average Price ($), Historic, 2000-2007 86
Figure 60: Needle Free Injections, United States, Average Price ($), Forecast,
2007-2012 87
Figure 61: Needle Free Injections, United States,
Distribution Share (%), 2006 88
Figure 62: Needle Free Injections, United
States, Company Share (%), 2006 89
Figure 63: 3M Company, Value Chain
Analysis 144
Figure 64: Baxter International Inc., Value Chain
Analysis 157
Figure 65: Hospira, Inc., Value Chain Analysis 170
Figure 66: Medical Equipment Approval Process in the United States, 2007
179
Figure 67: PMA Approval Process in the United States, 2007 181
Figure 68: The 510(k) Approval Process for Medical Devices in the United
States, 2007 182
Figure 69: Reimbursement Structure in the United States,
2007 187
Figure 70: Distribution Structure of Medical Equipment in the
United States, 2006 188
